Cargando…
Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis
OBJECTIVE: We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS: Glucose production was investigated in isolated hepatocytes and during pancreatic cla...
Autores principales: | Conti, Roberto, Mannucci, Edoardo, Pessotto, Pompeo, Tassoni, Emanuela, Carminati, Paolo, Giannessi, Fabio, Arduini, Arduino |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028366/ https://www.ncbi.nlm.nih.gov/pubmed/21270274 http://dx.doi.org/10.2337/db10-0346 |
Ejemplares similares
-
Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency
por: Hamilton-Craig, I., et al.
Publicado: (2012) -
Bone scinitigraphy in rhabdomyolysis associated with carnitine palmitoyl transferase deficiency
por: Wong, Jonathan, et al.
Publicado: (2010) -
Overproduction, Purification, and Stability of the Functionally Active Human Carnitine Acetyl Transferase
por: Giudice, Deborah, et al.
Publicado: (2022) -
The Reversible Carnitine Palmitoyltransferase 1 Inhibitor (Teglicar) Ameliorates the Neurodegenerative Phenotype in a Drosophila Huntington’s Disease Model by Acting on the Expression of Carnitine-Related Genes
por: Bertapelle, Carla, et al.
Publicado: (2022) -
Nutrition and Exercise in a Case of Carnitine Palmitoyl-Transferase II Deficiency
por: Parimbelli, Mauro, et al.
Publicado: (2021)